Cothera Bioscience
Developing cancer therapies for
undruggable targets
Latest News
Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma
San Francisco December 7, 2023 – Cothera Bioscience, a clinical stage biotech company developing therapeutics for previously undruggable oncology targets with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation